These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25994537)

  • 1. [Treatment of pancreatic cancer. Actuality and perspective].
    Bittoni A; Andrikou K; Lanese A; Santoni M; Pellei C; Faloppi L; Del Prete M; Giampieri R; Cascinu S
    Recenti Prog Med; 2015 May; 106(5):208-16. PubMed ID: 25994537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma].
    Delpero JR; Turrini O; Raoul JL
    Rev Prat; 2015 Mar; 65(3):382-9. PubMed ID: 26016202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Advances in the Treatment of Metastatic Pancreatic Cancer.
    Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
    Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
    Diab M; Azmi A; Mohammad R; Philip PA
    Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
    Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
    Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the challenges of pancreatic cancer: future directions for improving outcomes.
    Hidalgo M; Cascinu S; Kleeff J; Labianca R; Löhr JM; Neoptolemos J; Real FX; Van Laethem JL; Heinemann V
    Pancreatology; 2015; 15(1):8-18. PubMed ID: 25547205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for advanced pancreatic cancer: a review.
    Warsame R; Grothey A
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1327-36. PubMed ID: 23176620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
    Hessmann E; Johnsen SA; Siveke JT; Ellenrieder V
    Gut; 2017 Jan; 66(1):168-179. PubMed ID: 27811314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second line treatment options for pancreatic cancer.
    Passero FC; Saif MW
    Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
    Sullivan KM; Kozuch PS
    Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab: still an option in the treatment of pancreatic cancer?
    Faloppi L; Andrikou K; Cascinu S
    Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Metastatic Pancreatic Adenocarcinoma.
    Cheema AR; O'Reilly EM
    Surg Clin North Am; 2016 Dec; 96(6):1391-1414. PubMed ID: 27865284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment of advanced pancreatic cancer.
    Heinemann V; Haas M; Boeck S
    Cancer Treat Rev; 2012 Nov; 38(7):843-53. PubMed ID: 22226241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?
    Varadhachary GR; Wolff RA
    J Oncol Pract; 2016 Sep; 12(9):797-805. PubMed ID: 27621332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.
    Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ
    Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.